000727082 000__ 04593cam\a2200445Ii\4500
000727082 001__ 727082
000727082 005__ 20230306140759.0
000727082 006__ m\\\\\o\\d\\\\\\\\
000727082 007__ cr\cn\nnnunnun
000727082 008__ 150513s2015\\\\njua\\\\ob\\\\001\0\eng\d
000727082 020__ $$a9781607614241$$qelectronic book
000727082 020__ $$a1607614243$$qelectronic book
000727082 020__ $$z9781607614234
000727082 0247_ $$a10.1007/978-1-60761-424-1$$2doi
000727082 035__ $$aSP(OCoLC)ocn908838864
000727082 035__ $$aSP(OCoLC)908838864
000727082 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dGW5XE$$dIDEBK$$dYDXCP$$dCOO$$dEBLCP
000727082 049__ $$aISEA
000727082 050_4 $$aRC632.L5
000727082 08204 $$a616.3997$$223
000727082 24500 $$aDyslipidemias$$h[electronic resource] :$$bpathophysiology, evaluation and management /$$cAbhimanyu Garg.
000727082 264_1 $$aTotowa, NJ :$$bHumana Press,$$c2015.
000727082 300__ $$a1 online resource :$$bcolor illustrations.
000727082 336__ $$atext$$btxt$$2rdacontent
000727082 337__ $$acomputer$$bc$$2rdamedia
000727082 338__ $$aonline resource$$bcr$$2rdacarrier
000727082 4901_ $$aContemporary endocrinology
000727082 504__ $$aIncludes bibliographical references and index.
000727082 5050_ $$aLipoprotein Physiology -- Epidemiology of Blood Lipids and Lipoproteins -- Lipoprotein(a) -- Lipoproteins and Cardiovascular Disease Risk -- Detection and Treatment of Children and Adolescents with Dyslipidemia -- Type 2 Diabetes Mellitus and Dyslipidemia -- Type 1 Diabetes Mellitus and Dyslipidemia -- Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome -- Dyslipidemia in HIV-infected Patients -- Monogenic Hypercholesterolemia -- Primary Hypertriglyceridemia -- Genetic Disorders of HDL Metabolism -- Sitosterolemia and Other Rare Sterol Disorders -- Genetic Abetalipoproteinemia & Hypobetalipoproteinemia -- Drug-induced Dyslipidemia -- Lipodystrophies and Dyslipidemias -- Novel Genes for Dyslipidemias: Genome-Wide Association Studies -- Perspectives on Cholesterol Guidelines -- Nutrition and Coronary Heart Disease Prevention -- Phytosterol Therapy -- N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease -- Polyphenols for Cholesterol Management -- Dietary Supplements for Cholesterol Management -- Statins: Risk-Benefits and Role in Treating Dyslipidemias -- Fibrates: Risk-Benefits and Role in Treating Dyslipidemias -- Niacin: Risk-Benefits and Role in Treating Dyslipidemias -- Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias -- Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias -- Low Density Lipoprotein (LDL) Apheresis -- Novel Lipid Lowering Agents.
000727082 506__ $$aAccess limited to authorized users.
000727082 520__ $$aDyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists. For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Programs Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field. A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.
000727082 588__ $$aOnline resource; title from PDF title page (viewed May 14, 2015)
000727082 650_0 $$aLipids$$xMetabolism$$xDisorders$$xPathophysiology.
000727082 7001_ $$aGarg, Abhimanyu,$$eeditor.
000727082 77608 $$iPrint version:$$z9781607614234
000727082 830_0 $$aContemporary endocrinology (Totowa. N.J.)
000727082 852__ $$bebk
000727082 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-1-60761-424-1$$zOnline Access$$91397441.1
000727082 909CO $$ooai:library.usi.edu:727082$$pGLOBAL_SET
000727082 980__ $$aEBOOK
000727082 980__ $$aBIB
000727082 982__ $$aEbook
000727082 983__ $$aOnline
000727082 994__ $$a92$$bISE